John Crowley on Rare Disease Drug Development and US Biotech Competition with China

The Golden Age of Medicine and Man-Made Hurdles

• 💡 The current era is described as a golden age of medicine, with diseases like cystic fibrosis being cured.
• ⚠️ However, significant challenges preventing life-saving treatments from reaching patients are man-made, stemming from issues within the industry and regulatory processes.
• 💰 Capital is being denied to innovators, and the regulatory process introduces risk and uncertainty, leading to excessive time, cost, and inconsistency in drug development.

Impact of Regulatory Challenges on Innovation

• 📉 These hurdles raise the cost of capital, resulting in fewer companies being formed and fewer new technologies advancing.
• ⏳ The process takes too much time, too much money, and involves too much uncertainty and inconsistency, hindering the development of new medicines.
• 🇺🇸 Outdated drug regulatory policies are weakening the US as a global leader in rare disease treatment development.

The Rise of China's Biotech Industry

• 🇨🇳 China has streamlined its drug development regulatory process, making it cheaper and faster to develop new treatments there.
• 📈 Over the last two decades, China has seen a massive growth in R&D biotech companies, from a couple of hundred to over 4,000 today.
• 🚀 Chinese companies are now utilizing very high technology and are developing treatments better and faster than before.

Modernizing the FDA for Competitive Advantage

• 🎯 There's a need to avoid applying the same standards for rare diseases affecting a hundred children as for diseases affecting millions.
• ⚙️ A unique and flexible regulatory environment is required, necessitating leadership at the FDA.
• 🔬 A modernized and efficient FDA is crucial for the US to out-compete China in biotech innovation and bring hope to millions with rare diseases.

John Crowley's Personal Journey and Leadership

• 👨‍👩‍👧‍👦 John Crowley's journey began as a parent of two children with Pompe disease, a rare condition requiring him to develop a treatment himself.
• 🏆 He dedicated over 20 years to developing treatments, resulting in his children being alive and thriving today.
• 🏢 Crowley previously served as CEO of Amicus Therapeutics and is currently the head of the biotech industry group BIO.